Literature DB >> 25443607

Clopidogrel resistance: the way forward.

Shuvanan Ray1.   

Abstract

Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of Stent Thrombosis. This review article tries to find out the causes of Clopidogrel Resistance, the main factors involving it, Laboratory evaluation of Clopidogrel Resistance. The overall incidence of Clopidogrel Resistance across the Globe & India has also been considered. The article also discusses the clinical significance of Clopidogrel Resistance & its relationship with adverse cardiovascular events. This review ends with the probable solutions to Clopidogrel Resistance & the new generation of antiplatelets which can be used for the same.
Copyright © 2014 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clopidogrel resistance; Platelet reactivity; Prasugrel; Stent thrombosis; Ticagrelor

Mesh：

Substances：

Year:  2014        PMID： 25443607      PMCID： PMC4223168          DOI： 10.1016/j.ihj.2014.08.012

Source DB:  PubMed          Journal:  Indian Heart J        ISSN： 0019-4832


  24 in total

1.  Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.

Authors:  Rakhee Kar; Arvind Meena; Birendra K Yadav; Rakesh Yadav; Sitanshu Sekhar Kar; Renu Saxena
Journal:  Platelets       Date:  2012-06-21       Impact factor: 3.862

2.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

Authors:  Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'Neil; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-02-21       Impact factor: 29.690

3.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kirk Guyer; Peter W Cho; Kazi A Zaman; Rolf P Kreutz; Ashwani K Bassi; Udaya S Tantry
Journal:  J Am Coll Cardiol       Date:  2005-10-21       Impact factor: 24.094

4.  Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.

Authors:  Paul A Gurbel; Kevin P Bliden; Kazi A Zaman; Jason A Yoho; Kevin M Hayes; Udaya S Tantry
Journal:  Circulation       Date:  2005-02-28       Impact factor: 29.690

5.  Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.

Authors:  B Aleil; C Ravanat; J P Cazenave; G Rochoux; A Heitz; C Gachet
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

6.  Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.

Authors:  Nicolas von Beckerath; Dirk Taubert; Gisela Pogatsa-Murray; Edgar Schömig; Adnan Kastrati; Albert Schömig
Journal:  Circulation       Date:  2005-10-31       Impact factor: 29.690

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

9.  Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.

Authors:  Wei C Lau; Paul A Gurbel; Paul B Watkins; Charlene J Neer; Amy S Hopp; David G M Carville; Kirk E Guyer; Alan R Tait; Eric R Bates
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

10.  Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

Authors:  Zhongren Ding; Soochong Kim; Robert T Dorsam; Jianguo Jin; Satya P Kunapuli
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113
View more
  12 in total

1.  Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.

Authors:  Mirjana Novkovic; Dragan Matic; Jelena Kusic-Tisma; Nebojsa Antonijevic; Dragica Radojkovic; Ljiljana Rakicevic
Journal:  Eur J Clin Pharmacol       Date:  2017-12-19       Impact factor: 2.953

2.  Application of a TEG-Platelet Mapping Algorithm to Guide Reversal of Antiplatelet Agents in Adults with Mild-to-Moderate Traumatic Brain Injury: An Observational Pilot Study.

Authors:  Svetlana Kvint; Alexis Gutierrez; Anya Venezia; Eileen Maloney; James Schuster; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2022-06-16       Impact factor: 3.210

3.  The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.

Authors:  Ahmet İlker Tekkeşin; Adnan Kaya; Yasin Çakıllı; Ceyhan Türkkan; Mert İlker Hayıroğlu; Edibe Betül Borklu; Koray Kalenderoğlu; Ayca Gümüşdağ; Özlem Yıldırımtürk; Emrah Bozbeyoğlu; Mustafa Adem Tatlısu; Ahmet Taha Alper
Journal:  Anatol J Cardiol       Date:  2016-04-25       Impact factor: 1.596

Review 4.  A Review of Danshen Combined with Clopidogrel in the Treatment of Coronary Heart Disease.

Authors:  Zhaojian Zhang; Yu Wang; Wangxiao Tan; Siwei Wang; Jinghua Liu; Xiao Liu; Xiaoying Wang; Xiumei Gao
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-19       Impact factor: 2.629

5.  Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).

Authors:  Renan Sukmawan; Erick Hoetama; Siska Suridanda Danny; Astuti Giantini; Erlin Listiyaningsih; Vidya Gilang Rejeki; Amir Aziz Alkatiri; Isman Firdaus
Journal:  Pharmacol Res Perspect       Date:  2021-04

6.  Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention.

Authors:  S Ramesh; S Socrates; M A Rajasekaran; N Senguttuvan
Journal:  Indian Heart J       Date:  2020-09-09

7.  Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus?

Authors:  Jialin Sun; Jing Li; Ping Leng; Chen Sun; Wen Xu; Zhenhuan Zhao; Xiao Li; Xiaolei Zhang
Journal:  Pharmgenomics Pers Med       Date:  2020-11-23

8.  Platelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome.

Authors:  Edem Efe; Ibrahim Kocayiğit; Pabuccu Mustafa Türker; Küçükukur Murat; Alpaslan Erkan; Taş Sedat; Çil Alper; Aksoy Murat Necati; Vural Mustafa Gökhan; Akdeniz Bahri
Journal:  Indian J Pharmacol       Date:  2016 Jul-Aug       Impact factor: 1.200

9.  Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention.

Authors:  Bin Yang; Chunyan Zheng; Haichu Yu; Rui Zhang; Shan Li; Lijuan Tan; Min Leng; Shanglang Cai
Journal:  Iran J Public Health       Date:  2018-07       Impact factor: 1.429

Review 10.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy.

Authors:  Bhawani Yasassri Alvitigala; Lallindra Viranjan Gooneratne; Godwin Roger Constantine; Rajapaksha Arachchige Namal Kumarasiri Wijesinghe; Liyanage Dona Ashanthi Menuka Arawwawala
Journal:  Pharmacol Res Perspect       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.